| 2018-04-04 |
Gregg A. Lapointe, CPA, MBA, age 59, joined us as director in November 2017. ... Mr. Lapointe joined the Audit Committee on October 31, 2017. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2017: Gregg A. Lapointe Fees Earned or Paid in Cash $14,250 Option Awards $192,440 Total $206,690. |
| 2020-04-01 |
Gregg A. Lapointe, CPA, MBA, age 61, joined us as director in November 2017. ... The following three directors are the current members of the Audit Committee: Mr. Goodwin, Mr. Katkin and Mr. Lapointe. ... The following three directors are the members of the Corporate Governance, Health Care Compliance Oversight and Nominating Committee: Mr. Lapointe, Dr. Kotzin and Ms. Wasman, who replaced Dr. Ringrose upon his retirement in May of 2019, with Mr. Lapointe serving as Chair. ... For services provided in 2019, each non-employee director received, paid on a quarterly basis for quarters served, a yearly retainer of $50,000. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2019: Gregg A. Lapointe Fees Earned or Paid in Cash $77,000, Option Awards $22,917, Total $99,917. |
| 2021-04-06 |
Gregg A. Lapointe, CPA, MBA, age 62, joined us as director in November 2017. ... The following three directors are the current members of the Audit Committee: Mr. Lapointe ... The Corporate Governance, Health Care Compliance Oversight and Nominating Committee: Mr. Lapointe ... The following three directors are the members of the Scientific and Clinical Trial Advisory Committee: Dr. Moos, Dr. Kotzin and Ms. Wasman. Dr. Kotzin serves as Chair. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2020: Gregg A. Lapointe Fees Earned or Paid in Cash $77,000, Option Awards $62,695, Total $139,695. |
| 2024-04-10 |
Mr. Lapointe is currently the Chairman of the Board. The Chairman of the Board has authority, among other things, to call and preside over Board meetings, including meetings of the independent directors, to set meeting agendas and to determine materials to be distributed to the Board. The following directors are currently members of the Audit Committee: Ms. Ali-Jackson, Ms. Wasman and Mr. Lapointe. Mr. Lapointe serves as Chair. The following directors are currently members of the Compensation Committee: Dr. Moos, Ms. Ali-Jackson, and Mr. Lapointe. Dr. Moos serves as Chair. All members of Rigel’s Compensation Committee are independent. In 2023, each of our non-employee directors received stock option and RSU grants under our 2018 Plan. Option grants to the non-employee directors in 2023 were non-discretionary. The exercise price of options granted to non-employee directors under the 2018 Plan is 100% of the fair market value of our common stock on the date of the option grant, which is equal to the closing price of our stock on the grant date. The Board administers the 2018 Plan such that (a) initial option grants to non-employee directors vest in equal monthly installments over the shorter of three years from the date of grant or the period beginning on the date the director is appointed to the Board and ending on the date of the annual meeting at which the director is first considered for election by the stockholders, provided that the non-employee director continues to provide services to us and (b) annual option grants to non-employee directors vest in equal monthly installments over one year from the date of grant. The term of options granted to non-employee directors under the 2018 Plan is 10 years. RSUs vest on the date prior to the next Company’s Annual Meeting. In the event of a merger of the Company with or into another corporation or a consolidation, acquisition of assets or other change of control transaction involving us, each option will either continue in effect, if we are the surviving entity, or, if neither assumed nor substituted, will accelerate and the option will terminate if not exercised prior to the consummation of the transaction. For services provided in 2023, each non-employee director received, paid on a quarterly basis for each quarter served, a yearly retainer of $50,000. The Chairman of the Board received an additional $40,000. In addition, the Audit Committee chair received an additional yearly retainer of $22,000, the Corporate Governance, Health Care Compliance Oversight and Nominating Committee (Governance Committee) chair received an additional yearly retainer of $15,000, the Compensation Committee chair received an additional yearly retainer of $15,000, and the Scientific & Clinical Trial Advisory Committee Chair received an additional yearly retainer of $15,000. Each non-chair member of the Audit Committee received an additional yearly retainer of $12,000. Each non-chair member of the Compensation Committee received an additional yearly retainer of $10,000. Each non-chair member of the Governance Committee received an additional yearly retainer of $10,000. Each non-chair member of the Finance Committee received an additional yearly retainer of $5,000. Each non-chair member of the Scientific & Clinical Trial Advisory Committee received an additional yearly retainer of $10,000. In the fiscal year ended December 31, 2023, the total cash compensation earned by all non-employee directors as a group was $556,000. |